PHARMAESSENTIA
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases.
PHARMAESSENTIA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.pharmaessentia.com
Total Employee:
51+
Status:
Active
Contact:
+886-2-2655-7688
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Employees Featured
Founder
Stock Details
Investors List
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Post-IPO Equity - PharmaEssentia
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-03 | PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer |
Official Site Inspections
http://www.pharmaessentia.com Semrush global rank: 1.87 M Semrush visits lastest month: 11.86 K
- Host name: 156.208.209.35.bc.googleusercontent.com
- IP address: 35.209.208.156
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "PharmaEssentia"
PharmaEssentia - Crunchbase Company Profile
Organization. PharmaEssentia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... PharmaEssentia Corporation is a biopharmaceutical company that develops โฆSee details»
About PharmaEssentia - About Us - PharmaEssentia โฆ
2022. Oct PharmaEssentia hold the groundbreaking ceremony of the Zhubei plant.; Jun PharmaEssentia honored at the National Organization of Rare Disorders (NORD®) 2022 Rare Impact Awards for the introduction of โฆSee details»
PharmaEssentia Medical Affairs
The PharmaEssentia Medical Affairs team is a strategic thought partner dedicated to providing comprehensive educational, clinical, and scientific information about PharmaEssentia โฆSee details»
PharmaEssentia - LinkedIn
PharmaEssentia | 10,650 followers on LinkedIn. Better Science, Better Lives. | PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global โฆSee details»
PharmaEssentia Corp. 2023 Annual Report
The U.S. subsidiary of PharmaEssentia Corporation in 2023 exhibited considerable growth compared with last year. As of December 2023, the combined cumulative revenue of โฆSee details»
Executives - About Us - PharmaEssentia-Ropeginterferon alfa โฆ
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases. The Companyโs world-class cGMP biologics facility in Taichung is certified by the โฆSee details»
PharmaEssentia Corp. 2020 Annual Report
E-mail: [email protected] Tel: 886-2-2655-7688 Acting Spokesperson: Muriel Hwang Title: Senior Manager E-mail: [email protected] Tel: 886-2-2655-7688 2. The address and โฆSee details»
PharmaEssentia - Contacts, Employees, Board Members, Advisors โฆ
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis, and other diseases.See details»
PHARMAESSENTIA USA EXPANDS LEADERSHIP WITH EXECUTIVE โฆ
โWith tremendous progress just in the last year, our U.S. organization is now expanding a strong bench of leaders who bring expertise, passion and lessons from their careers to help us โฆSee details»
PharmaEssentia Corp - Company Profile and News - Bloomberg โฆ
PharmaEssentia Corporation develops and distributes therapeutic products for treatment in human disease. The Company develops drugs to treat hepatitis, chronic myeloid leukemia โฆSee details»
PharmaEssentia - Overview, News & Similar companies - ZoomInfo
Mar 16, 2023 PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary โฆSee details»
PharmaEssentia Company Profile - Craft
PharmaEssentia is a biotech company focused on the areas of hematology, oncology, dermatology, and infectious diseases. Its lead compound is ropeginterferon alfa-2b, an โฆSee details»
Patient Stories - PharmaEssentia
Ray Urbanski joined PharmaEssentia in 2020 as SVP and Head of Clinical Development and Medical Affairs for the U.S. organization. An established clinical researcher, licensed clinician โฆSee details»
PharmaEssentia-Ropeginterferon alfa-2b,P1101,PV,polycythemia โฆ
PharmaEssentia develops treatments for myeloproliferative neoplasms, hepatitis and other diseases. The Companyโs world-class cGMP biologics facility in Taichung is certified by the โฆSee details»
PharmaEssentia - VentureRadar
PharmaEssentia specializes in the development of innovative biologic drugs, with a focus on Ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV). The company โฆSee details»
PharmaEssentia Company Profile 2024: Stock Performance
PharmaEssentia was founded in 2003. Where is PharmaEssentia headquartered? PharmaEssentia is headquartered in Taipei, Taiwan. What is the size of PharmaEssentia? โฆSee details»
PHARMAESSENTIA EXPANDS U.S. LEADERSHIP WITH ANJANA โฆ
โPharmaEssentia is at a pivotal point of growth and I am excited to join the team in a full-time role to help the organization realize its vision by expanding and growing its already incredible talent โฆSee details»
What We Do | Transformative Medicine in Hematology & More
PharmaEssentia has extensive knowledge in PEGylated cytokines, which led to the successful launch of BESREMi, the best-in-class interferon-ษ and the only FDA-approved treatment โฆSee details»
Chapter Highlights - pharmaessentia-esg.com
In 2023, PharmaEssentia completed the application for the IND of the Phase 1 TFDA clinical trial in Taiwan for the treatment of solid tumors with anti-PD-1 antibody (P1801). and the multi โฆSee details»